H. Lundbeck (CPSE:HLUN B) - Cotización, noticias y análisis

Resumen de acción HLUN B

Análisis fundamental de HLUN B
Puntuación del snowflake
Valoración	5/6
Crecimiento futuro	1/6
Rendimiento pasado	3/6
Salud financiera	5/6
Dividendos	3/6

Recompensas

Cotiza un 72.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 8.57%

Los beneficios han crecido un 7% al año en los últimos 5 años

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

No se han detectado riesgos en HLUN B a partir de nuestros controles de riesgos.

Competidores de H. Lundbeck A/S

ALK-Abelló

CPSE:ALK B

DKK 34.9b

Novo Nordisk

CPSE:NOVO B

DKK 3.2t

Genmab

CPSE:GMAB

DKK 92.1b

Changchun High-Tech Industry (Group)

SZSE:000661

CN¥44.4b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de H. Lundbeck
Precios históricos de las acciones
Precio actual de la acción	DKK 44.72
Máximo en las últimas 52 semanas	DKK 49.38
Mínimo de 52 semanas	DKK 31.62
Beta	0.18
1Cambio en 1 mes	-5.85%
Variación en 3 meses	2.62%
Cambio de 1 año	33.89%
3Variación en 3 años	n/a
Variación en 5 años	n/a
Variación desde la OPV	37.60%

Noticias y actualizaciones recientes

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Quite Sensibly

Oct 24

Recent updates

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

Rentabilidad de los accionistas

	HLUN B	DK Pharmaceuticals	Mercado DK
7D	2.3%	-3.3%	-3.1%
1Y	33.9%	3.5%	5.7%

Rentabilidad vs. Industria: HLUN B superó a la industria Danish Pharmaceuticals, que obtuvo un rendimiento del 3.5% el año pasado.

Rentabilidad vs. Mercado: HLUN B superó al mercado Danish, que obtuvo un rendimiento del 5.7% el año pasado.

Volatilidad de los precios

Is HLUN B's price volatile compared to industry and market?
HLUN B volatility
HLUN B Average Weekly Movement	4.0%
Pharmaceuticals Industry Average Movement	5.3%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.4%

Precio estable de las acciones: HLUN B no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de HLUN B (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1951	5,800	Charl van Zyl	www.lundbeck.com

H. Lundbeck A/S, empresa biofarmacéutica, se dedica a la investigación, desarrollo, producción y venta de productos farmacéuticos para el tratamiento de trastornos psiquiátricos y neurológicos en Europa, Estados Unidos e internacionalmente. Los principales productos de la empresa son Abilify Maintena/Abilify Maintena para la esquizofrenia y el trastorno bipolar I en adultos; Brintellix/Trintellix para el tratamiento de los trastornos depresivos; Northera para el tratamiento de la hipotensión ortostática neurógena sintomática; Vyepti para la prevención de la migraña; y Rexulti/Rxulti para el tratamiento del TDM y la esquizofrenia. También suministra Azilect para tratar la enfermedad de Parkinson; Cipralex/Lexapro para la depresión; Ebixa para tratar la demencia; Onfi para la epilepsia; Sabril para el tratamiento de las crisis parciales complejas refractarias y los espasmos infantiles; Xenazine para la corea; Deanxit para la depresión; Cipramil para la depresión y la ansiedad; y Cisordinol para tratar la psicosis.

Resumen de fundamentos de H. Lundbeck A/S

¿Cómo se comparan los beneficios e ingresos de H. Lundbeck con su capitalización de mercado?
Estadísticas fundamentales de HLUN B
Capitalización bursátil	DKK 42.66b
Beneficios(TTM)	DKK 2.69b
Ingresos (TTM)	DKK 21.44b

16.5x

Ratio precio-beneficio (PE)

2.1x

Ratio precio-ventas (PS)

¿Está HLUN B sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de HLUN B
Ingresos	DKK 21.44b
Coste de los ingresos	DKK 4.37b
Beneficio bruto	DKK 17.07b
Otros gastos	DKK 14.39b
Beneficios	DKK 2.69b

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

Feb 05, 2025

Beneficios por acción (BPA)	2.71
Margen bruto	79.63%
Margen de beneficio neto	12.53%
Ratio deuda/patrimonio	15.6%

¿Cómo se ha desempeñado HLUN B a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.6%

Rentabilidad actual por dividendo

26%

Ratio de pagos

Resumen de acción HLUN B

Recompensas

Análisis de riesgos

Competidores de H. Lundbeck A/S

CPSE:ALK B

DKK 34.9b

CPSE:NOVO B

DKK 3.2t

CPSE:GMAB

DKK 92.1b

SZSE:000661

CN¥44.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Quite Sensibly

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Quite Sensibly

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

Investors Aren't Entirely Convinced By H. Lundbeck A/S' (CPH:HLUN B) Earnings

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Price target increased by 9.4% to kr.45.54

Do H. Lundbeck's (CPH:HLUN B) Earnings Warrant Your Attention?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investors Interested In H. Lundbeck A/S' (CPH:HLUN B) Earnings

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Key Executive recently bought kr.751k worth of stock

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de H. Lundbeck A/S

16.5x

2.1x

Beneficios e Ingresos

Dividendos

1.6%